NCT02333305View on ClinicalTrials.gov

Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Ataxia-oculomotor Apraxia 1
Interventions
DIETARY_SUPPLEMENT

CoQ10

• 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)

OTHER

Sanomit Placebo

• according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day

Trial Locations (1)

75013

ICM Institute, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02333305 - Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 | Biotech Hunter | Biotech Hunter